Navigation Links
Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
Date:9/2/2008

c journals -- Circulation and the Journal of Thrombosis and Haemostasis.

Regado is currently evaluating REG1 in 26 patients undergoing elective percutaneous coronary intervention (PCI). The multi-center, open-label, randomized Phase IIa study designated REVERSAL-PCI will assess whether REG1 can replace standard heparin therapy during the performance of PCI with stenting.

REG1 is the first specific, direct-acting anticoagulant controllable by its matched reversal agent. Regado is developing REG1 for use in patients suffering from acute coronary syndrome who undergo coronary revascularization procedures. These procedures, which include percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG), put patients at a high risk for therapy-related bleeding complications. REG1 is being developed initially to increase therapeutic flexibility and improve patient outcomes in coronary revascularization procedures. Intellectual property covering this technology derives from work originating in Duke University Medical Center's Division of Surgical Sciences, which was not involved in the subsequent clinical studies. Duke exclusively licensed the technology to Regado and will receive certain payments from Regado under this license.

REG1 is a two-component system, consisting of an aptamer-based anticoagulant and its matched reversal agent. The REG1 anticoagulant component, RB006, is a single-stranded, nucleic acid aptamer. RB006 selectively and potently binds to and inhibits factor IXa, a protein that is critical to blood coagulation. The reversal agent, RB007, is a complementary nucleic acid that binds to and neutralizes RB006. The amount of RB007 administered allows physicians to fine tune the pharmacodynamic effect of RB006, from slight reduction in anticoagulation all the way to complete reversal.

About Regado Biosciences

Regado Biosciences is pioneering a new therapeutic field with the discovery and development of two-c
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
2. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
3. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
4. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
5. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
6. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
7. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
8. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
9. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
10. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
11. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 14, 2014 The Brandeis Medical Center, led by Dr. ... premier and affordable laser tattoo removal experience with the advanced Astanza ... in providing high quality cosmetic services with cutting edge medical technology ... Southern California has seen a dramatic increase in ...
(Date:1/14/2014)... Animal Emergency Critical Care, a LifeCentre partner practice, located at 165 ... the first in Loudoun County to receive ... Susan M. Barnes , Medical Director, is a well-seasoned veterinarian of ... Taylor , are avid scuba divers. "As altitude skiers and hikers, ...
(Date:1/14/2014)... N.Y. , Jan. 14, 2014   Oligomerix, Inc. , ... modifying therapeutics for Alzheimer,s disease (AD) and related neurodegenerative ... to Valhalla, NY as of ... laboratory space at New York Medical College. ...
Breaking Medicine Technology:Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... March 7, 2012  Solta Medical, Inc. (NASDAQ: ... market, today provided an update on the launch of ... approved by the FDA. A majority ... comprised of leading plastic surgeons and dermatologists, who received ...
...  Discovery Laboratories, Inc. (NASDAQ: DSCO ), a ... in respiratory critical care, will hold a conference call ... its March 6th announcement that SURFAXIN (lucinactant) has been ... Distress Syndrome (RDS) in premature infants at high risk ...
Cached Medicine Technology:Solta Medical Provides Update on Liposonix Launch 2Solta Medical Provides Update on Liposonix Launch 3Solta Medical Provides Update on Liposonix Launch 4Media Alert: Discovery Labs to Hold Conference Call to Discuss FDA Approval of SURFAXIN® (lucinactant) 2
(Date:4/18/2014)... of your worst memories? How did it make you ... a negative personal experience, such as how sad you ... emotional distress, especially when you can,t stop thinking about ... thinking about the context of the memories, rather than ... way to alleviate the negative effects of these memories, ...
(Date:4/18/2014)... ― A new study in the American Journal ... Google searches reveals a recurring pattern that could be ... Investigators from San Diego State University, the Santa Fe ... "healthy" Google searches (searches that included the term healthy ... the U.S. from 2005 to 2012. They found that ...
(Date:4/17/2014)... of chronic inflammation in benign prostate tissue was ... this association was found even in those with ... study published in Cancer Epidemiology, Biomarkers & ... for Cancer Research. , An analysis of prostate ... placebo arm of the Prostate Cancer Prevention Trial ...
(Date:4/17/2014)... that could be used to provide relief from ... made the discovery when researching how pain occurs ... , Dr Marzia Malcangio said: "We have been ... our findings could help chemotherapy patients who suffer ... effect of some chemotherapy drugs (such as vincristine) ...
(Date:4/17/2014)... Experimental Biology and Medicine a multidisciplinary ... Paul Kenis in the Institute of Genomic Biology ... Illinois Urbana-Champaign describe their recent work on subcellular ... of cell functions including energy metabolism, signaling, and ... regulating normal cellular behavior, redox status has been ...
Breaking Medicine News(10 mins):Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:New research shows people are thinking about their health early in the week 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3Health News:New pain relief targets discovered 2Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2
... the Hebrew University of Jerusalem have discovered that Vav1 ... one of the factors in tumorous tissue growth -- plays ... previously been thought. The discovery has implications for further concentration ... work of the researchers, led by Dr. Shulamit Katzav-Shapira of ...
... 2010) International experts and scientists will present ... life of stockpiled drugs to identifying unlabeled substances ... of the 2010 International Pharmaceutical Federation (FIP) Pharmaceutical ... American Association of Pharmaceutical Scientists (AAPS) Annual Meeting ...
... , MONDAY, Nov. 8 (HealthDay News) -- A new ... can be inherited. As part of the Framingham Foot ... participants between 2002 and 2005, researchers studied 675 people ... towards the smaller toes (known as hallux valgus), and 154 ...
... an electrical switch allows the flow of electricity into electrical ... optical switch allowing the flow of light through otherwise opaque ... Los Alamos National Laboratory delivers a 200 terawatt power pulse ... States) in half a trillionth of a second (picosecond) time. ...
... study suggests joint complaints attributed to aromatase inhibitors (AI), ... arthritis or autoimmune disease. Because of that, researchers ... of arthritis should be encouraged to continue taking the ... Tuesday, Nov. 9 at the 74th Annual Scientific Meeting ...
... GA Lupus puts children at higher risk for ... using statins doesn,t provide enough benefit to warrant their ... largest study of pediatric lupus patients to date. ... and organ damage. Children with lupus show early signs ...
Cached Medicine News:Health News:Hebrew University researchers discover expanded role for cancer-causing gene 2Health News:Common Foot Disorders Can Be Inherited, Research Shows 2Health News:Plasma as a fast optical switch 2Health News:Joint pain linked to breast cancer drug not inflammatory arthritis or autoimmune disease 2Health News:Statins don't prove useful for general pediatric lupus population 2
Eliminate preanalytical errors with automated QC module....
Non-invasive and continuous tcpCO2 and tcpO2 patient monitoring....
... Submit your analyzer data via the ... a worldwide peer group. , ... you to perform statistical analysis of ... often as you like. Peer-group data ...
Automated QC module...
Medicine Products: